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SerotypesInfection with bovine papillomavirus type 1 (BPV1) or BPV2 induces ﬁbropapillomas in cows and skin
sarcoids in horses. Prophylactic vaccination targeting BPV1 and BPV2 may reduce the incidence of these
economically important diseases. The L1 major capsid proteins of BPV1 and BPV2 were expressed in Sf-9
insect cells and both self-assembled into virus-like particles (VLPs). Using conformation-dependent
monoclonal antibodies (mAb) both type-speciﬁc and shared epitopes were detected. Antisera were raised
against BPV1 or BPV2 VLP using alum adjuvant, and their (cross)neutralization capacity was tested by C127
neutralization assays using native BPV1 and BPV2 virions, or by BPV1 pseudovirion assay. Antisera induced
by either VLP vaccine were able to robustly (cross-)neutralize heterologous as well as homologous types,
indicating that BPV1 and BPV2 are closely related serotypes. These results suggest that a monovalent BPV1
(or BPV2) VLP vaccine may potentially protect against both BPV1 and BPV2 infections and associated
diseases.
© 2009 Elsevier Inc. All rights reserved.Introduction
Papillomaviruses (PV) comprise a large family of small DNA tumor
viruses that infect the epithelia of skin and mucosa of many animal
species and humans causing benign hyperproliferations, papillomas
or warts. Respective ten bovine papillomavirus types (BPV1-10) have
been characterized, 9 of which cause papillomas of skin and teats
(BPV1-3 and BPV5-10), whereas BPV4 causes tumors of the upper
gastrointestinal tract in animals feeding bracken fern (Nasir and
Campo, 2008). The most important types BPV1 and BPV2 (genus
delta) are unusual in their ability to infect both the epithelial cells and
the ﬁbroblasts of the underlying dermis, causing ﬁbropapillomas of
the skin, teats and udders, as well as urinary bladder cancer in the cow
(Nasir and Campo, 2008). Similar to other papillomaviruses BPV1/2
replication and virion production is conﬁned to the epithelial portion
of the lesion, while ﬁbroblastic infection is non-productive. Lesions
normally regress as a result of a cellular immune response, which
appears to protect against re-infection with that type. However, in
some animals papillomas persist or even widely spread due to the
inability to reject the infection, thus necessitating slaughtering of the
animal. In addition, BPV1/2 may persist as latent infection and
become reactivated by immunosuppression and/or physical trauma.at (R. Kirnbauer).
ll rights reserved.(Campo et al., 1994). Similar to human papillomavirus (HPV)
infections (Frazer, 2009) genetic host factors that control innate
immunity and effector T-cell responses may determine the increased
risk of persisting infection.
The only known natural infection outside the primary host is
infection of horses and other ungulates with BPV1 or BPV2 causing the
development of sarcoids, a non-productive chronic infection of the
skin. The ability of BPV1 and BPV2 to non-productively transform
non-epithelial cells is not species-speciﬁc, although the increased host
range is limited to ﬁbroblasts as further shown by the induction of
experimental ﬁbroblastic tumors in hamsters, and focal transforma-
tion of cultured rodent cells (Howley and Lowy, 2007). Sarcoids are
locally invasive ﬁbroblastic skin tumors with reported prevalence
from 13–67%, representing themost common equine neoplasm (Nasir
and Campo, 2008). Genomic DNA of BPV1 or BPV2 can be detected
episomally (non-integrated into the host genome) in the vast
majority of these tumors. Currently, there is no effective therapy for
sarcoids. Thus worldwide sarcoids result in signiﬁcant economic
losses both in the agrarian economy of developing countries (by
affecting donkeys at an estimated 0.6 cases/animal/year) and the
horse industry (Nasir and Campo, 2008).
Similar to results in later HPV vaccine studies, prophylactic
vaccination with recombinantly expressed L1 virus-like particles
(VLPs) of BPV4, which is not closely related to BPV1 or BPV2,
protected cows against experimental BPV4 challenge with high
efﬁcacy, but had no therapeutic effect on established tumors
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the induction of neutralizing antibodies, which are mainly restricted
to the types present in the vaccine, but may partially extend to closely
related types (Brown et al., 2009; Wheeler et al., 2009).
BPV1 and BPV2 are distinct genotypes, as deﬁned by their 84%
nucleotide homology of the L1 gene. Their L1 amino acid sequence
identity reaches 92%, which is comparable to the similarity of HPV6/
11 (92%) or HPV18/45 (87%). Limited studies have been performed on
the serological relationship between BPV1 and BPV2 (Dvoretzky et al.,
1980). However, the ability of a BPV1 or BPV2 VLP vaccine to induce
cross-neutralization of the respective heterologous type has not been
examined.
A prophylactic VLP-based vaccine to prevent equine sarcoids
should prevent both BPV1 and BPV2 infections. Here we evaluated the
serotypes of BPV1 and BPV2 by probing the capsids with neutralizing
monoclonal and polyclonal antibodies. In addition, neutralization
assays were performed with homologous and heterologous anti-VLP
antisera using infectious virions in focus-forming neutralization
assays, or using a recently available BPV1 pseudovirion assay. The
results demonstrate that BPV1 and BPV2 are closely related serotypes,
indicating that a monovalent BPV1 (or BPV2) VLP vaccine may sufﬁce
to protect against both BPV1 and BPV2 infections and associated
diseases.
Results and discussion
BPV1 and BPV2 VLPs partly share neutralization epitopes
BPV1 VLPs were generated by expression of L1 in insect cells and
puriﬁed on density gradients as described previously (Kirnbauer et al.,
1992). To generate BPV2 VLP, the L1 open reading frame (ORF) was
ampliﬁed from genomic BPV2 DNA in an analogous manner, cloned
into the baculovirus expression vector pEVmod, and veriﬁed by
sequencing. Following the generation of recombinant baculoviruses,
BPV2 L1 was expressed in Sf-9 insect cells and veriﬁed by SDS-PAGE
and Coomassie staining, and Western blotting using the non-
neutralizing monoclonal antibody (mAb) AU-1 (raised against
BPV1). AU-1 recognizes the linear BPV1-L1 epitope DTYRYI, which isFig. 1. Expression of major capsid protein L1 of BPV1 and BPV2 in Sf-9 insect cells. L1 of BP
density gradient centrifugation. Crude cell lysates and puriﬁed VLPs were separated by SDS-P
raised against BPV1 L1 (at a dilution of 1/10,000). Both L1 proteins migrated as 55 kD pro
Molecular weight (MW)markers are indicated. Non-infected (Sf-9) or wt baculovirus-infecte
were negatively stained with 1% uranylacetate and visualized at a magniﬁcation×30,000. Spredicted to also exist in BPV2-L1. As expected by their close
homology, puriﬁed BPV1 and BPV2-L1 proteins migrated similarly
as 55 kD proteins on a Coomassie stained gel (Fig. 1a, lanes 4 and 6).
Western blotting demonstrated a major immunoreactive band of
55 kD in cell lysates and puriﬁed VLP preparation for both BPV types
(Fig. 1b, lanes 3–6), as predicted, but not in control lysates of
uninfected or wild type baculovirus-infected Sf-9 cells (Fig. 1b, lanes 1
and 2). Smaller bands likely represent degraded proteins, as observed
for over-expressed L1 proteins of various papillomavirus types.
Puriﬁed BPV1 and BPV2 preparations were further examined by
negative staining and transmission electron microscopy (TEM),
demonstrating self-assembly into VLP of about 60 nm in diameter
and a morphology similar to other papillomavirus types (Fig. 1c).
The major neutralization epitopes of papillomaviruses are confor-
mation-dependent and located on the surface loops of the assembled
L1 capsid or pentamers. To examine if BPV1 and BPV2 VLPs share
cross-reactive epitopes, ELISA were performed under non-denaturing
(native) conditions (Fig. 2). Sera of rabbits vaccinated with L1 VLP of
either BPV1 or BPV2 were analyzed for their ability to react to the
homologous and heterologous types. In addition, VLPs were probed
with mAb to conformation-dependent epitopes of BPV1. Particles
were dispersed into thewells and incubated in triplicates with 10-fold
serial antibody dilutions ranging from 10−2 to 10−5 (Figs. 2a, b). Both
antisera recognized BPV1 and BPV2 VLPs by ELISA with a titer of
10,000, indicating, as expected, that antibodies can be generated in
rabbits that cross-react to the respective heterologous type. However,
it is likely that at least part of the observed cross-reactivity may be
attributable to linear non-neutralizing epitopes that are exposed on
partially disassembled VLP or denatured protein. This is in agreement
with the reactivity for both BPV types to AU-1, which recognizes a
linear L1 epitope (Figs. 1, 2) (Ghim, Young, and Jenson, 1996). MAb
B1.C4, B1.D7, and B1.F12 have been raised to BPV1 VLP, and mAb B1.
A1 and 5B6 have been raised to BPV1 virions. As shown in Figs. 2a, b,
two types of antibody binding pattern were observed. MAb B1.C4 and
B1.D7 recognize both BPV1 and BPV2-L1 VLPs, with B1.D7 being less
reactive to BPV2 as compared to BPV1. In contrast, 5B6, B1.F12, and
B1.A1 reactivity was restricted to BPV1 VLP. These results indicated
that BPV1 and BPV2 VLPs share conformation-dependent epitopesV1 and BPV2 were expressed by recombinant baculoviruses and VLPs were puriﬁed by
AGE and visualized by Coomassie staining (a), or Western blotting (b) using mAb AU-1
teins. Faster migrating immunoreactive bands likely represent degradation products.
d cells served as controls. For transmission electronmicroscopy (TEM) (c) puriﬁed VLPs
cale bar represents 200 nm.
Fig. 2. Serologic analysis of BPV1 and BPV2 by VLP ELISA and virion neutralization assays. BPV1 VLP (a) or BPV2 VLP (b) were analyzed under non-denaturing (native) conditions
using antisera raised to BPV1-L1 and BPV2-L1 VLPs, and mAb directed to conformational BPV1 epitopes. VLPs were incubated with 10-fold serial dilutions (10−2 to 10−5) of
antibodies. Data are expressed as mean OD±SD of triplicate wells. Neutralization capacity of antibodies at ﬁnal dilution of 1:100 was determined by C127 focus-forming
neutralization assays using BPV1 (a) or BPV2 (b) native virions. +, Neutralizing, −, non-neutralizing; n.d., not determined.
3Rapid Communicationthat are detectable by some mAb on both VLPs. In addition, other
epitopes exist that are type-speciﬁc as shown by mAb reactivity
restricted to BPV1.
BPV1/BPV2 virion and BPV1 pseudovirion neutralization assays
Efﬁcacy of papillomavirus vaccines correlates with their capacity
to induce neutralizing serum antibodies, which are sufﬁcient to
protect against experimental infection (Breitburd et al., 1995; Suzich
et al., 1995). Thus we next determined whether antisera induced by
VLP vaccination were neutralizing against the respective homologous
and heterologous types. Infectious BPV1 or BPV2 virions were
incubated with antisera raised against homologous or heterologous
VLP type for 1 h before infection of C127 mouse ﬁbroblasts. Following
3 weeks of maintenance, cultures were stained to detect focally
transformed cells indicating successful infectious events (Dvoretzky
et al., 1980). As shown in Fig. 3a, innumerable foci developed in
cultures infected with BPV1 virions incubated with preimmune
serum. In contrast anti-BPV1 serum neutralized with a titer of 1000,
whereas anti BPV2 antisera neutralized with a titer of 100 (≥ 50%
reduction of the number of foci obtained with preimmune serum).
Likewise, when analyzed for BPV2 neutralization (Fig. 3b) both anti-
BPV1 and anti-BPV2 sera neutralized with a titer of 1000 (one
representative of at least 3 independent experiments for both types is
shown). As shown previously, antisera raised against denatured VLP
or heterologous HPV16 VLP do not neutralize BPV1 virions (Kirnbauer
et al., 1992; Roden et al., 1996). We also employed BPV1 pseudovir-
ions (Buck et al., 2005) for testing rabbit antisera to BPV2- and BPV1-
L1 VLPs for neutralization capacity. Antisera to BPV1 and BPV2 VLPs
(cross)neutralized BPV1 pseudovirions with a titer of 1000 and 100,
respectively, whereas an anti-HPV16 VLP antiserum used as control
was non-neutralizing (not shown).These results show that both BPV1 and BPV2 VLPs can induce
neutralizing antisera to their homologous type, as well as cross-
neutralization to the heterologous type. Given that the neutralizing
activity for both BPV1 VLP and BPV2 VLP antisera is no more than one
order of magnitude less against the heterologous virus comparedwith
that against the homologous virus, this clearly indicated that BPV1
and BPV2 are closely related serotypes. An implication of these results
is that a monovalent vaccine, composed of VLPs from BPV1 or BPV2, is
likely to confer a similar degree of protection against the heterologous
virus as against the homologous virus.
We next determined the relative capacity of the mAb to BPV1 to
neutralize infectious BPV1 and BPV2. Native virions were extracted
from two different cow warts and viral DNAs genotyped by L1
sequencing. Results indicated the presence of BPV1 or BPV2,
respectively, with similar degree of nucleotide relatedness as those
in GenBank (not shown). As indicated by focus-forming neutralization
assays,mAb 5B6, B1.C4, B1.F12, and B1.A1 (dilution 1:100) neutralized
BPV1 virions, whereas B1.D7 was non-neutralizing (Fig. 2a). In
contrast, none of the mAb was able to neutralize BPV2 (not tested
for B1.F12), whether or not they were reactive to BPV2 VLP by ELISA
(Fig. 2b). The type-speciﬁcity of the monoclonal as compared to the
polyclonal antibodies reﬂects the differences in epitope diversity
recognized by these two reagents. Monoclonal antibodies recognize a
single epitope, and a single amino acid change within this epitope can
eliminate this binding (as we have shown in the case of mAb H16.E70
binding to HPV16 L1 of one variant but not another (Roden et al.,
1997)). It is noteworthy that the principal immunodominant neutral-
izing epitopes of L1 contain the great majority of amino acid changes
between variants and types. By contrast, polyclonal antibodies
recognize a plurality of epitopes, such that a single change in one
epitope is unlikely to impact its reactivity signiﬁcantly (consistent
with the cross-neutralization of all HPV16 variants tested by antisera
Fig. 3. Comparison of antisera to BPV1 and BPV2 VLPs by focus-forming neutralization assays. Infectious BPV1 (a) or BPV2 virions (b) puriﬁed from cow warts were pre-incubated
with immune sera, plated onto C127 ﬁbroblasts, maintained for 3 weeks with regular feeding, and stained. Control plates received either no virus (cells only) or virus incubated with
preimmune serum at 10−2 dilution. Antisera raised against BPV1- or BPV2-L1 VLP were serially diluted 10-fold from 10−2 to 10−5 as indicated. Neutralization titers are scored
visually as the reciprocal of the highest serum dilution that results in ≥50% reduction in the number of foci obtained with preimmune serum.
4 Rapid Communicationto a singleHPV16 variant L1 VLP (Cheng et al., 1995)).We also envision
other less likely explanations, including immunization bias in mice
towards generating a type-speciﬁc rather than cross-neutralizing
immune response, or selection bias for hybridomas by using BPV1
capsids. Surprisingly, B1.C4 that bound both VLP and virion types by
ELISA (Fig. 2) or FACS (not shown), proved only neutralizing to BPV1,
but not BPV2 virions, indicating a subtle difference in the epitopes'
sequence, structure or function between the types.
By analogy to the results of VLP vaccines in humans, and
experimental vaccination in cows, it is likely that a VLP vaccine will
protect against both epidermal and dermal infections in cows (Campo,
1997; Kirnbauer et al., 1996; Paavonen et al., 2007; Villa et al., 2005).
However, it is unknown whether it would protect against dermal
infection in horses and thus be as effective in protecting against
sarcoids, as it seems possible that details of the pathogenesis of the
dermal infection in cows and horses may be different in ways that
might have implications for vaccine efﬁcacy. In cows most dermal
infectionmay be derived from progeny virus that has replicated in the
overlying epidermis. VLP vaccines may be highly effective in part
because they interfere with the ability of progeny virus to spread to
secondary sites of infection. In horses, by contrast, there is no progenyvirus that is known to develop, in the epidermis or the dermis.
Therefore, it is likely that the dermal infection in horses arises de novo
from external virions. Although these incoming virions would be
neutralized by the systemic antibodies, this supposition remains to be
proven. We are currently conducting BPV1 VLP vaccination trials to
evaluate efﬁcacy against experimental challenge in horses.
Human VLP vaccine studies have shown stabilized vaccine titers
and high protective efﬁcacy at least 6 years after vaccination. By
analogy, this is well within the time range of lactation in cows
requiring effective protection. The potential for long-term vaccine
efﬁcacy in horses, mules and donkeys, which may stay up to several
decades in use remains to be determined.
The N-terminus of L2 contains broadly cross-neutralization
epitopes that are shared by cutaneous and mucosal types. Vaccina-
tions with the L2 minor capsid protein induced low-titer antibodies
and protected cattle and rabbits against challenge with the homol-
ogous virus type at both cutaneous and mucosal sites (Campo, 1997;
Embers et al., 2002; Pastrana et al., 2005; Roden et al., 1994). Although
BPV1 and BPV2 appear as the most important types causing diseases
in ungulates, a vaccine including L2may offer even broader protection
against additional pathogenic BPV types (Nasir and Campo, 2008).
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Recombinant baculovirus expression vectors
To generate recombinant baculovirus for expression of the major
capsid protein L1 of BPV2, the L1 open reading frame was ampliﬁed
from genomic clone pAT153-BPV2 (kindly provided by Saveria
Campo, Glasgow) between nucleotides (nt) 5601–7139, by polymer-
ase chain reaction (PCR) using a combination of high-ﬁdelity
(proofreading) Pwo Isis and Taq DNA polymerases (Qbiogene, MP
Biomedicals, Irvine, California) at a ratio of 5:1. Primers incorporate 5′
an EcoRI restriction enzyme (RE) site (underlined) CCGCTGAATTCAA-
TATGGCGTTGTGGCAACAAG, and 3′ a KpnI site GCGGTGGTACCGTT-
GACTTACCTTATGGTTCAC. The amplimer was cloned into the
baculovirus transfer vector pEV mod (Kirnbauer et al., 1992). Final
clones were veriﬁed by RE digest and DNA sequencing.
Following co-transfection of Sf-9 insect cells with transfer vector
and linearized baculovirus DNA (BaculoGold, BD Biosciences Phar-
mingen, San Diego, CA), recombinant baculoviruses were obtained by
plaque puriﬁcation, and high-titer viral stocks generated. Sf9 insect
cells were infected at high multiplicity of infection (MOI) for three
days, lysed by sonication, and high molecular mass structures
separated by sucrose and cesium chloride gradient ultra-centrifugation
asdescribed (Shafti-Keramat et al., 2003). The virus-likeparticles (VLP)-
containing bandwas collected and dialyzed against phosphate buffered
saline (PBS)/0.5 M NaCl/1mMCaCl2/0.01% Brij 58. Generation of BPV1
L1-expressing baculovirus has been reported previously (Kirnbauer et
al., 1992). To analyze integrity of puriﬁed VLP, particle preparations
were negatively stained with 1% uranyl acetate and analyzed by
transmission electron microscopy (TEM) using a JEOL 1010 electron
microscope at 80 kV and × 30,000 magniﬁcation.
SDS-PAGE and Western blot
Aliquots of puriﬁed VLP or crude cell lysates were analyzed by
sodium dodecyl-sulfate (SDS)-polyacrylamide gel electrophoreses
(PAGE) and Western blot. Brieﬂy, samples were denatured in SDS
sample buffer containing 2% beta-mercaptoethanol and electrophor-
esed on 10% SDS-PAGE. Following separation proteins were either
stained with Coomassie brilliant blue, or immunoblotted and probed
overnight at 4 °C with monoclonal antibody (mAb) AU-1 (1/10,000).
Finally blots were incubated with second-step peroxidase-labeled
goat-anti-mouse (1/40,000) (BIO-RAD Laboratories, Hercules, CA)
and developed using the ECL-system (Pierce, Biotechnologies, Rock-
ford, IL).
Polyclonal and monoclonal antibodies
Fifty μg of puriﬁed VLP was administered to NZW rabbits (Charles
River, Kisslegg, Germany) four times, the ﬁrst boost four weeks after
ﬁrst injection, then in two week intervals, using aluminum hydroxide
as adjuvant. Monoclonal antibodies B1.C4, B1.D7, and B1.F12 have
been raised to BPV1 VLP, and mAb B1.A1 and 5B6 have been raised to
BPV1 virions (Christensen and Kreider, 1993; Roden et al., 1994), all of
which recognize conformational epitopes. Non-neutralizing mAb AU-
1 recognizes the linear BPV1-L1 epitope DTYRYI (BabCo, Berkeley
Antibody, Richmond, CA). MAb H16.V5 and 5B6 are neutralizing for
HPV16 and BPV 1, respectively.
Isolation of BPV1 and BPV2 virions from cow warts
Cow warts containing BPV1 or BPV2 infectious virions were
kindly provided by Richard Roden, Johns Hopkins University, and
Wayne Lancaster, Wayne State University. Warts were minced with
a scalpel, re-suspended in PBS and frozen in liquid nitrogen.
Subsequently the tissue was mechanically disrupted for 3 minusing a Swing mill MM200 (Retsch, Haan, Germany), centrifuged at
10,000 g, 4 °C, for 5 min, and the supernatant containing virions was
stored in aliquots at −70 °C. To verify the BPV type, viral DNA was
isolated by proteinase K digest, the L1 ORF was ampliﬁed by PCR
using primers GCATCCCTCCTTGTTGAGG (nt 5543–5561) and
GTTGACTTACCTTATGGTTCAC (nt 7118–7139) and the DNA sequence
was obtained.
VLP enzyme-linked immunosorbent assay (ELISA)
Native L1 VLPs were used as antigen in enzyme-linked immuno-
sorbent assay (ELISA) as described (Kirnbauer et al., 1994). For
denaturing L1 ELISA, proteins were dried onto the ELISA plate in
denaturing buffer (0.2 M NaHCO3/0.01 M DTT/pH 10.6) at 37 °C
overnight.
BPV 1 pseudovirion neutralization assay
Pseudovirions were generated by co-transfection of 293 TT cells
with plasmids pSheLL and pSEAP, and neutralization assays were
performed as described (Buck et al., 2005). BPV 1 pseudovirions were
incubated for 1 h at 37 °C/5% CO2with serial dilutions of mAb or rabbit
immune sera and placed on 293 TT cells. Incubation with AU-1
(BabCo, Richmond, CA), H16.V5, 5B6, antisera to BPV1-L1 VLP and
preimmune sera of the same animals served as appropriate controls.
Secreted alkaline phosphatase (SEAP) content in the supernatants
was determined using p-nitrophenyl phosphate (Sigma, St. Louis,
MO) dissolved in diethanolamine (Acros Organics, NJ), and OD values
measured at 405 nm. Immune IgG dilutions showing at least 50%
reduction in SEAP activity as compared to preimmune IgG were
considered neutralizing. Data shown are the mean±SD of triplicate
wells of a representative experiment.
BPV1 and BPV2 virion neutralization assays (C127 focus formation)
BPV1 or BPV2 virions were incubated with ten-fold serial
dilutions of immune sera in 1 ml serum-free RPMI medium (Gibco)
and plated onto sub-conﬂuent mouse C127 ﬁbroblasts in 60 mm
dishes for 1 h at 37 °C (Dvoretzky et al., 1980). RPMI medium
supplemented with 5% FCS was added, plates were maintained for
about 3 weeks with periodic feeding, and stained with methanol/5%
methylene blue/2.5% carbolfuchsin. Endpoint neutralization titers
were scored as the reciprocal of the highest serum dilution that
resulted in ≥ 50% reduction in the number of foci obtained with
preimmune sera.
Flow cytometric analysis (FACS)
HaCaT cells were trypsinized and incubated in RPMI medium/5%
FCS for 1 h at 37 °C. VLP (BPV1-L1 or BPV2-L1) or virions (BPV1 or
BPV2) were bound to 1×105 HaCaT cells for 1 h at 4 °C in FC buffer
(PBS/2% fetal bovine serum/0.01% sodium azide) as described (Day et
al., 2007). Cells were washed to remove unbound particles and mAb
5B6, B1.C4, anti BPV1-L1, or mAb H16.V5 (HPV16-neutralizing) as a
control, respectively, were added at a ﬁnal concentration of 1 μg/ml
and incubated for 1 h at 4 °C in FC buffer. Cells were washed again
with FC buffer, incubated with ﬂuorescein isothiocyanate-labeled
goat-anti-mouse IgG (H+L) (Alexa Fluor 488; Molecular Probes) for
1 h at 4 °C, and analyzed on a Becton Dickinson FACScan.
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